Organoid models as an alternative to experiments with animals
After validation in animal models, more than 9 in 10 drugs that enter human clinical trials fail because they are unsafe or ineffective. Since December 2022, new medicines need not to be tested in animals to receive U.S. Food and Drug Administration (FDA) approval because the Agency can rely on animal-free alternatives before human trials (Wadman, Science 2023). In our lab, we are incorporating human organoids and organ chips to advance in the pre-clinical characterization of new antivirals. Our goal is to participate in the development of new experimental models as an alternative to the use of animals in research.
After validation in animal models, more than 9 in 10 drugs that enter human clinical trials fail because they are unsafe or ineffective. Since December 2022, new medicines need not to be tested in animals to receive U.S. Food and Drug Administration (FDA) approval because the Agency can rely on animal-free alternatives before human trials (Wadman, Science 2023). In our lab, we are incorporating human organoids and organ chips to advance in the pre-clinical characterization of new antivirals. Our goal is to participate in the development of new experimental models as an alternative to the use of animals in research.